What Is the JAK2 V617F Mutation and What Does It Mean?

JAK2 V617F is a single-letter change in a gene that tells the bone marrow how many blood cells to make, and it leaves that signal stuck in the “on” position.¹ The marrow keeps producing blood cells even when the body hasn’t asked for them, which drives a group of slow-growing blood cancers.² The change is picked up during life in blood-forming cells and isn’t passed down in families, so finding it doesn’t mean your children carry it.³

Having the mutation is not by itself a diagnosis. What it means depends on your blood counts, your marrow findings, and how much of the mutation your blood carries.

What the Mutation Actually Changes in Your Blood Cells

The name describes the exact swap. At position 617 of the JAK2 protein, the building block valine (V) is replaced by phenylalanine (F).⁴ That happens because a single letter of DNA in the JAK2 gene has changed, from G to T.⁵

Normally JAK2 only switches on when hormones such as erythropoietin, the kidney’s signal to make red cells, attach to the cell.⁶ The mutation sits in the part of the protein that normally holds it switched off, so the protein stays active without any signal.⁷ Mutated marrow cells therefore respond to tiny amounts of growth hormones, or grow without them at all.⁸ The always-on JAK2 pushes several growth and survival pathways that help mutated cells outgrow normal ones.⁹

The takeover is gradual. The mutation starts in a single blood-forming stem cell, and its offspring grow a bit faster and survive a bit longer than normal cells. Over years they make up a larger share of the blood. That slow pace is why these conditions are usually chronic rather than sudden.

Because the change arises in a stem cell in the marrow, it shows up in the blood cells descended from that cell and not in skin, muscle, or other organs. A cheek swab or a test on non-blood tissue wouldn’t find it; the test is done on a blood sample, and sometimes on marrow.

Which Blood Conditions It Points To

These conditions are a type of chronic blood cancer called myeloproliferative neoplasms, or MPNs. A positive JAK2 V617F result is one of the main criteria doctors use to diagnose an MPN, but only alongside blood counts and often a bone marrow biopsy, since the mutation can also be found in people without an MPN. A negative result doesn’t rule out ET or myelofibrosis, since about half of people with them lack the mutation.¹⁴ If you test negative but your counts stay high, ask whether testing for other MPN-linked gene changes, such as CALR or MPL, is planned.

MPNs are classed as blood cancers because they come from one abnormal cell line. Still, most people live many years, often decades, managed with monitoring and medicines, and these conditions behave very differently from fast-moving leukemias. Ask your hematologist about your specific outlook. The same change can lead to excess red cells in one person and excess platelets in another, depending on the amount of mutation and which cell types carry it.

After a positive result, doctors typically look at your complete blood count first, since high red cells, platelets, or white cells are what prompt the search for the mutation. They may add blood tests such as an erythropoietin level, and a bone marrow biopsy to see how the marrow cells look under the microscope.

Finding It Without a Blood Disease

Some people carry JAK2 V617F in a small share of their blood cells without meeting the criteria for an MPN.¹⁵ Even in this setting, the mutation is linked to blood clot problems.¹⁶ In people who’d had strokes, those carrying even small amounts of JAK2 V617F more often had other blood-cell mutations too.¹⁷

This finding often turns up in genetic testing done after a stroke or clot, or in broad DNA panels done for other reasons. Counts can be normal at the time. The usual plan is to watch counts over time rather than treat right away, so if it’s found incidentally, ask about regular blood count checks and your clot risk.

Having a small mutated group of cells does not mean an MPN is present or will develop; most people with such findings never develop one. The concern is that clot risk and the chance of later change are somewhat higher than in people without the mutation, which is why follow-up is suggested.

Blood Clots Are the Main Everyday Risk

In people with ET, carrying the mutation roughly doubles the risk of a blood clot.¹⁸ That rise applies to both vein clots, such as in the legs or lungs, and artery clots, such as heart attack and stroke.¹⁹ In one group with ET, about 36% of those with the mutation had a first clot, compared with 16% of those without.²⁰ The mutation makes platelets more easily activated, irritates blood vessel linings, and drives inflammation.²¹ Age, a past clot, and high blood counts raise risk further.²²

Sometimes a clot in a liver or gut vein (Budd-Chiari syndrome or portal vein thrombosis) is the first sign of an MPN.²³ Testing for JAK2 V617F in people with these clots and no other signs found an MPN in about 1 in 6.²⁴ Doctors now routinely test for it after these unusual clots.

Know the warning signs of a clot:

Leg swelling, pain, or warmth on one side
Sudden breathlessness or chest pain
Face drooping, arm weakness, or speech trouble, which signal a possible stroke
Sudden abdominal pain or swelling, which can signal an abdominal vein clot

Any of these needs emergency care.

To lower the risk, many people take low-dose aspirin unless they have a reason not to. In PV, regular blood removal keeps red cell levels down, and drugs to lower counts are added for higher-risk people. Not smoking and managing blood pressure and cholesterol help too.

A normal blood count doesn’t mean no clot risk, since the mutation affects how platelets and vessel walls behave, not only how many cells you have. Clot risk is judged from your age, clot history, and counts together, not from the mutation alone.

What the Percentage on Your Report Means

Your report may list “allele burden” or “variant allele frequency (VAF)” as a percentage. That is the share of JAK2 gene copies in your blood cells that carry the change. Each cell has two copies of the gene, and a cell can carry the change in one or both. So a result of about 25% could mean half your white cells have one mutated copy, or a quarter have both.²⁵

Cells start with one mutated copy, but sometimes a cell later loses its normal copy and duplicates the mutated one, leaving two. This is common in PV. Cells with two mutated copies can signal more strongly, which is one reason higher percentages are linked with a more advanced picture.

In PV, an allele burden above 50% raises the risk of progressing to myelofibrosis.²⁶ In the same group, the number did not predict leukemia or clots.²⁷

Modern tests reliably measure levels down to 1%, and some detect far less.²⁸ The number is one piece alongside counts and symptoms; ask whether your doctor will recheck it and how often. Different labs’ methods can give somewhat different numbers,²⁹ so try to have repeat tests done at the same lab to track changes fairly.

Is It Inherited and What Raises the Odds

The mutation is found in blood-forming cells but not in the DNA you were born with.³⁰ You can’t pass the mutation itself to your children. Even so, MPNs are more common in people with a family history of them and in people of Jewish descent.³¹

That tendency raises the odds without guaranteeing anything; most relatives of someone with an MPN never develop one. Routine testing of relatives usually isn’t needed. Relatives with high counts or unusual clots should tell their doctor about your diagnosis, and a strong family pattern of MPNs is worth raising with a hematologist.

The mutation is more common in smokers than nonsmokers.³² Jobs with possible benzene or petroleum exposure are linked to MPNs,³³ and being overweight and frequent infections may play a part in how it develops.³⁴ Stopping smoking is a useful step, since it also lowers clot risk.

How It Can Change Over Time

Over time PV or ET can turn into myelofibrosis, and a smaller number of people develop acute myeloid leukemia.³⁵ People with JAK2-positive primary myelofibrosis have a higher risk of turning into leukemia.³⁶ Extra mutations in other genes, such as TET2 or ASXL1, can pile up and make the abnormal cells more aggressive,³⁷ and these extra mutations don’t appear in a set order.³⁸ Most people with PV or ET live for many years without progressing, and change usually takes years when it does occur.

Signs that your condition may be changing include growing tiredness, night sweats, weight loss, or bone pain, and a feeling of fullness from an enlarging spleen. Counts can shift too, such as red cells falling after being high. Report these at follow-up rather than waiting. Most changes show first in routine blood counts, and catching change early opens more treatment options.

Treatments That Target JAK2

Ruxolitinib, a pill that blocks JAK1 and JAK2, was the first targeted drug approved for myelofibrosis and for PV that doesn’t respond to or tolerate hydroxyurea.³⁹ In myelofibrosis, about 4 in 10 people on it saw their enlarged spleen shrink by at least a third, versus almost none on placebo.⁴⁰ Symptoms and quality of life improved within about 8 weeks.⁴¹

It rarely clears the mutation, though. The share of mutated gene copies typically fell only about 7–22% after a year, and leukemia risk didn’t change.⁴² That’s because current drugs block normal JAK2 as well as the mutated form.⁴³

Ruxolitinib is taken by mouth, usually twice a day, with the dose adjusted to your blood counts. Common side effects include lower platelet or red cell counts, so regular blood tests are part of treatment. Stopping it suddenly can cause symptoms to return quickly, so any change should be made with your doctor.

Not everyone needs a JAK inhibitor. Many people with PV or ET are managed with aspirin, blood removal, or hydroxyurea, and JAK inhibitors are mainly for myelofibrosis or hard-to-control PV. The choice depends on clot risk, symptoms, and age.

Newer drugs in development aim to block only the mutated JAK2 and spare the normal version.⁴⁴ They could potentially remove mutated cells while avoiding drops in normal blood counts.⁴⁵ These are still in trials, so ask about clinical trials if standard treatment isn’t enough.

Useful questions for your hematologist:

Which MPN do I have, and how was it confirmed?
What is my allele burden, and will you track it?
What is my clot risk, and should I take aspirin?
What symptoms should make me call you?

1
PubMed. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases ↩︎
2
Cancer. New advances in the role of JAK2 V617F mutation in myeloproliferative neoplasms ↩︎
3
Atlas of Genetics and Cytogenetics in Oncology and Haematology. JAK2 mutations in myeloproliferative neoplasms ↩︎
4
Atlas of Genetics and Cytogenetics in Oncology and Haematology. JAK2 mutations in myeloproliferative neoplasms ↩︎
5
Atlas of Genetics and Cytogenetics in Oncology and Haematology. JAK2 mutations in myeloproliferative neoplasms ↩︎
6
PubMed. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases ↩︎
7
PubMed. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases ↩︎
8
PubMed. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases ↩︎
9
Blood. Synergistic Activity of Combinations of JAK2 Kinase Inhibitor with PI3K/mTOR, MEK or PIM Kinase Inhibitor Against Human Myeloproliferative Neoplasm Cells Expressing JAK2V617F ↩︎
10
PubMed. Features and Allele Frequency of JAK2 Exon 12-Mutated Polycythemia Vera in Comparison with JAK2V617F-Mutated Disease ↩︎
11
PubMed. Features and Allele Frequency of JAK2 Exon 12-Mutated Polycythemia Vera in Comparison with JAK2V617F-Mutated Disease ↩︎
12
PubMed. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis–impact on disease phenotype ↩︎
13
PubMed. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis–impact on disease phenotype ↩︎
14
PubMed. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis–impact on disease phenotype ↩︎
15
PubMed. Thrombosis, bleeding, and progression in JAK2 V617F clonal hematopoiesis ↩︎
16
Blood. Association between JAK2V617F-Clonal Hematopoiesis of Indeterminate Potential and Microthromboembolism-Related Diseases ↩︎
17
PubMed Central. Prevalence and impact of additional CHIP mutations in JAK2V617F‐positive ischaemic cerebrovascular patients ↩︎
18
PubMed. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review ↩︎
19
PubMed. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review ↩︎
20
Haematologica. Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia ↩︎
21
Ramathibodi Hospital, Mahidol University. JAK2-Mutation Promoted Thrombosis: From Basic Science to Treatment Approaches ↩︎
22
Ramathibodi Hospital, Mahidol University. JAK2-Mutation Promoted Thrombosis: From Basic Science to Treatment Approaches ↩︎
23
PubMed. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis ↩︎
24
PubMed. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis ↩︎
25
PubMed Central. Clinical relevance of JAK2 (V617F) mutant allele burden ↩︎
26
PubMed. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications ↩︎
27
PubMed. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications ↩︎
28
Haematologica. Concordance of assays designed for the quantification of JAK2V617F: a multicenter study ↩︎
29
Haematologica. Concordance of assays designed for the quantification of JAK2V617F: a multicenter study ↩︎
30
Atlas of Genetics and Cytogenetics in Oncology and Haematology. JAK2 mutations in myeloproliferative neoplasms ↩︎
31
PubMed. Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms ↩︎
32
PubMed Central. Environmental Factors, Lifestyle Risk Factors, and Host Characteristics Associated With Philadelphia Negative Myeloproliferative Neoplasm: A Systematic Review ↩︎
33
PubMed. Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms ↩︎
34
Blood Advances. JAK2V617F mutation is highly prevalent in patients with ischemic stroke: a case-control study ↩︎
35
PubMed. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications ↩︎
36
PubMed Central. Acute Myeloid Leukemia Evolving from JAK 2-Positive Primary Myelofibrosis and Concomitant CD5-Negative Mantle Cell Lymphoma: A Case Report and Review of the Literature ↩︎
37
Haematologica. JAK2V617F/TET2 mutations: does the order matter? ↩︎
38
Leukemia. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 ↩︎
39
PubMed Central. Targeted therapies for myeloproliferative neoplasms ↩︎
40
PubMed Central. Targeted therapies for myeloproliferative neoplasms ↩︎
41
PubMed Central. Targeted therapies for myeloproliferative neoplasms ↩︎
42
PubMed Central. Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications ↩︎
43
PubMed. Next-generation JAK inhibitors in the treatment of myeloproliferative neoplasms ↩︎
44
Blood. Preclinical characterization of a novel, wild-type-sparing, JAK2 V617F mutant-selective inhibitor ↩︎
45
Blood. Preclinical characterization of a novel, wild-type-sparing, JAK2 V617F mutant-selective inhibitor ↩︎